$RVMD news
The latest RVMD stock news: headlines, filings, AI summaries and sentiment for $RVMD, updated around the clock.
- Royalty Pharma Poised to Benefit from Revolution Medicines' FDA-Approved Pancreatic Cancer Drug
- Revolution Medicines Reports Q3 2026 Results Following RASONQUE Approval
- Revolution Medicines Reaffirms 2026 GAAP Operating Expense Guidance Following RASONQUE FDA Approval
- Revolution Medicines, Inc. - 10-Q Filing
- Revolution Medicines, Inc. - 8-K Filing
- Royalty Pharma Stock as a Diversified Alternative to Revolution Medicines
- Revolution Medicines Receives Approval for First Product RASONQUE in Pancreatic Cancer
- Revolution Medicines Prices New Pancreatic Cancer Drug at $39,800 per Month
- Revolution Medicines Achieves FDA Approval for Rasonque, Reaching $47B Valuation
- FDA approves first broad RAS-targeted drug for metastatic pancreatic cancer
- FDA approves first RAS-targeted pancreatic cancer drug from Revolution Medicines
- Revolution Medicines Receives FDA Approval for Rasonque; Analysts Forecast $11.5 Billion Peak Sales
- Revolution Medicines Shares Drop Despite First FDA Approval
- Revolution Medicines Receives FDA Approval for Rasonque One Month After Filing
- Barclays Analyst Predicts Biotech M&A Market Reopening After Prolonged Downturn
- Stanley Druckenmiller Invests in Revolution Medicines Amid Strong Clinical Results
- Stanley Druckenmiller and Wall Street Analysts Back Biotech Stock Revolution Medicines
- Stanley Druckenmiller Invests in Biotech Stock Revolution Medicines Amid Upcoming FDA Review
- Pomerantz Law Firm Announces Class Action Lawsuit Against Erasca, Inc.
- Berger Montague Announces Class Action Against Erasca (NASDAQ: ERAS) Over Alleged Securities Fraud
- Revolution Medicines Surges on Regulatory Progress and Backing from Stanley Druckenmiller
- Class Action Lawsuit Filed Against Erasca, Inc.
- Amplia Therapeutics Highlights Potential for Combination Therapy with KRAS Inhibition in Pancreatic Cancer
- Revolution Medicines, Inc. - 8-K Filing
- Tango Therapeutics Rises on Early-Stage Data for Vopimetostat in Pancreatic Cancer
- Revolution Medicines Reports Positive Phase 3 Trial Results for Pancreatic Cancer Drug
- Needham Maintains Buy Rating on Revolution Medicines Despite Wider Q1 Loss
- Revolution (RVMD) Q1 2026 Earnings Transcript Summary
- Royalty Pharma Reports Q1 2026 Earnings and Provides Updated Guidance
- Tom Steyer Remains Bullish on Revolution Medicines (RVMD)
- Erasca Shares Drop 48% After Patient Death in Early Cancer Drug Trial
- Erasca Reports Negative Phase 1 Trial Data, Shares Drop 37%
- Revolution Medicines Shares Rise 54% Following Positive Pancreatic Cancer Drug Trial Results
- Replimune Announces Staff Cuts, MeiraGTx Reacquires Eye Gene Therapy